Literature DB >> 20466726

Alpha-conotoxin AuIB isomers exhibit distinct inhibitory mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic acetylcholine receptors.

Anton A Grishin1, Ching-I A Wang, Markus Muttenthaler, Paul F Alewood, Richard J Lewis, David J Adams.   

Abstract

Non-native disulfide isomers of alpha-conotoxins are generally inactive although some unexpectedly demonstrate comparable or enhanced bioactivity. The actions of "globular" and "ribbon" isomers of alpha-conotoxin AuIB have been characterized on alpha3beta4 nicotinic acetylcholine receptors (nAChRs) heterologously expressed in Xenopus oocytes. Using two-electrode voltage clamp recording, we showed that the inhibitory efficacy of the ribbon isomer of AuIB is limited to approximately 50%. The maximal inhibition was stoichiometry-dependent because altering alpha3:beta4 RNA injection ratios either increased AuIB(ribbon) efficacy (10alpha:1beta) or completely abolished blockade (1alpha:10beta). In contrast, inhibition by AuIB(globular) was independent of injection ratios. ACh-evoked current amplitude was largest for 1:10 injected oocytes and smallest for the 10:1 ratio. ACh concentration-response curves revealed high (HS, 1:10) and low (LS, 10:1) sensitivity alpha3beta4 nAChRs with corresponding EC(50) values of 22.6 and 176.9 microM, respectively. Increasing the agonist concentration antagonized the inhibition of LS alpha3beta4 nAChRs by AuIB(ribbon), whereas inhibition of HS and LS alpha3beta4 nAChRs by AuIB(globular) was unaffected. Inhibition of LS and HS alpha3beta4 nAChRs by AuIB(globular) was insurmountable and independent of membrane potential. Molecular docking simulation suggested that AuIB(globular) is likely to bind to both alpha3beta4 nAChR stoichiometries outside of the ACh-binding pocket, whereas AuIB(ribbon) binds to the classical agonist-binding site of the LS alpha3beta4 nAChR only. In conclusion, the two isomers of AuIB differ in their inhibitory mechanisms such that AuIB(ribbon) inhibits only LS alpha3beta4 nAChRs competitively, whereas AuIB(globular) inhibits alpha3beta4 nAChRs irrespective of receptor stoichiometry, primarily by a non-competitive mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466726      PMCID: PMC2903359          DOI: 10.1074/jbc.M110.111880

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Differential targeting of nicotinic acetylcholine receptors by novel alphaA-conotoxins.

Authors:  R Jacobsen; D Yoshikami; M Ellison; J Martinez; W R Gray; G E Cartier; K J Shon; D R Groebe; S N Abramson; B M Olivera; J M McIntosh
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences.

Authors:  M Schnölzer; P Alewood; A Jones; D Alewood; S B Kent
Journal:  Int J Pept Protein Res       Date:  1992 Sep-Oct

3.  Alpha-conotoxins ImI and ImII target distinct regions of the human alpha7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes.

Authors:  Michael Ellison; Fan Gao; Hai-Long Wang; Steven M Sine; J Michael McIntosh; Baldomero M Olivera
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

4.  The role of the beta 4-subunit in determining the kinetic properties of rat neuronal nicotinic acetylcholine alpha 3-receptors.

Authors:  R L Papke; S F Heinemann
Journal:  J Physiol       Date:  1991       Impact factor: 5.182

5.  A method to identify protein sequences that fold into a known three-dimensional structure.

Authors:  J U Bowie; R Lüthy; D Eisenberg
Journal:  Science       Date:  1991-07-12       Impact factor: 47.728

6.  Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes.

Authors:  R Zwart; H P Vijverberg
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

7.  A noncompetitive peptide inhibitor of the nicotinic acetylcholine receptor from Conus purpurascens venom.

Authors:  K J Shon; M Grilley; R Jacobsen; G E Cartier; C Hopkins; W R Gray; M Watkins; D R Hillyard; J Rivier; J Torres; D Yoshikami; B M Olivera
Journal:  Biochemistry       Date:  1997-08-05       Impact factor: 3.162

Review 8.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.

Authors:  Layla Azam; J Michael McIntosh
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

9.  Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.

Authors:  Patrick H N Celie; Sarah E van Rossum-Fikkert; Willem J van Dijk; Katjusa Brejc; August B Smit; Titia K Sixma
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

10.  alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release.

Authors:  S Luo; J M Kulak; G E Cartier; R B Jacobsen; D Yoshikami; B M Olivera; J M McIntosh
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

View more
  24 in total

1.  Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5(D398N) variant.

Authors:  Andrew A George; Linda M Lucero; M Imad Damaj; Ronald J Lukas; Xiangning Chen; Paul Whiteaker
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Authors:  Ayman K Hamouda; Ze-Jun Wang; Deirdre S Stewart; Atul D Jain; Richard A Glennon; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2015-04-13       Impact factor: 4.436

3.  Identifying key amino acid residues that affect α-conotoxin AuIB inhibition of α3β4 nicotinic acetylcholine receptors.

Authors:  Anton A Grishin; Hartmut Cuny; Andrew Hung; Richard J Clark; Andreas Brust; Kalyana Akondi; Paul F Alewood; David J Craik; David J Adams
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

Review 4.  α-Conotoxins active at α3-containing nicotinic acetylcholine receptors and their molecular determinants for selective inhibition.

Authors:  Hartmut Cuny; Rilei Yu; Han-Shen Tae; Shiva N Kompella; David J Adams
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

5.  Chronic Menthol Does Not Change Stoichiometry or Functional Plasma Membrane Levels of Mouse α3β4-Containing Nicotinic Acetylcholine Receptors.

Authors:  Selvan Bavan; Charlene H Kim; Brandon J Henderson; Henry A Lester
Journal:  Mol Pharmacol       Date:  2019-01-22       Impact factor: 4.436

6.  The E Loop of the Transmitter Binding Site Is a Key Determinant of the Modulatory Effects of Physostigmine on Neuronal Nicotinic α4β2 Receptors.

Authors:  Xiaochun Jin; Megan M McCollum; Allison L Germann; Gustav Akk; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2016-11-28       Impact factor: 4.436

7.  Agonist Selectivity and Ion Permeation in the α3β4 Ganglionic Nicotinic Receptor.

Authors:  Anant Gharpure; Jinfeng Teng; Yuxuan Zhuang; Colleen M Noviello; Richard M Walsh; Rico Cabuco; Rebecca J Howard; Nurulain T Zaveri; Erik Lindahl; Ryan E Hibbs
Journal:  Neuron       Date:  2019-09-02       Impact factor: 17.173

Review 8.  Aqueous ionic liquids influence the disulfide bond isoform equilibrium in conotoxin AuIB: a consequence of the Hofmeister effect?

Authors:  Karuna Anna Sajeevan; Durba Roy
Journal:  Biophys Rev       Date:  2018-01-02

Review 9.  Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.

Authors:  Luis M Tuesta; Christie D Fowler; Paul J Kenny
Journal:  Biochem Pharmacol       Date:  2011-06-29       Impact factor: 5.858

10.  Presence of multiple binding sites on α9α10 nAChR receptors alludes to stoichiometric-dependent action of the α-conotoxin, Vc1.1.

Authors:  Dinesh C Indurthi; Elena Pera; Hye-Lim Kim; Cindy Chu; Malcolm D McLeod; J Michael McIntosh; Nathan L Absalom; Mary Chebib
Journal:  Biochem Pharmacol       Date:  2014-02-15       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.